HomeComparePQG vs ABBV

PQG vs ABBV: Dividend Comparison 2026

PQG yields 11.50% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $80.6K in total portfolio value
10 years
PQG
PQG
● Live price
11.50%
Share price
$15.65
Annual div
$1.80
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.7K
Annual income
$1.24
Full PQG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PQG vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPQGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PQG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PQG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PQG
Annual income on $10K today (after 15% tax)
$977.64/yr
After 10yr DRIP, annual income (after tax)
$1.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,054.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PQG + ABBV for your $10,000?

PQG: 50%ABBV: 50%
100% ABBV50/50100% PQG
Portfolio after 10yr
$62.0K
Annual income
$12,386.50/yr
Blended yield
19.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PQG
Analyst Ratings
6
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
333.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PQG buys
0
ABBV buys
0
No recent congressional trades found for PQG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPQGABBV
Forward yield11.50%3.06%
Annual dividend / share$1.80$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$21.7K$102.3K
Annual income after 10y$1.24$24,771.77
Total dividends collected$1.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: PQG vs ABBV ($10,000, DRIP)

YearPQG PortfolioPQG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,275$575.08$11,550$430.00$275.00ABBV
2$12,367$302.99$13,472$627.96$1.1KABBV
3$13,388$155.30$15,906$926.08$2.5KABBV
4$14,404$78.56$19,071$1,382.55$4.7KABBV
5$15,452$39.50$23,302$2,095.81$7.8KABBV
6$16,553$19.80$29,150$3,237.93$12.6KABBV
7$17,722$9.91$37,536$5,121.41$19.8KABBV
8$18,967$4.96$50,079$8,338.38$31.1KABBV
9$20,298$2.48$69,753$14,065.80$49.5KABBV
10$21,720$1.24$102,337$24,771.77$80.6KABBV

PQG vs ABBV: Complete Analysis 2026

PQGStock

PQ Group Holdings Inc. provides specialty catalysts, materials, chemicals, and services in the United States, the Netherlands, the United Kingdom, and internationally. The company operates through four segments: Refining Services, Catalysts, Performance Materials, and Performance Chemicals. The Refining Services segment offers sulfuric acid recycling and end-to-end logistics services to produce alkylate; and virgin sulfuric acid for water treatment, mining, and industrial applications. The Catalysts segment provides silica catalysts and zeolite catalysts for producers and licensors of polyethylene and methyl methacrylate. The Performance Materials segment offers transportation safety microspheres for various binders, such as paint and epoxy coatings; and engineered glass materials, including solid and hollow microspheres and particles for uses, such as strengthening and light-weighting in plastics and polymer additives, cleaning and peening of metal surfaces, and conductivity or shielding in electronic applications. The Performance Chemicals segment offers sodium silicates for construction, cleaning, water treatment, pulp and paper, foundry and refractory, green tires, electronics, and refining catalysts; and specialty silicas for use as ingredients in personal care products, foods, edible oils, and beers, as well as industrial uses consisting of gloss control in coil, wood, general industrial leather, and other surface coating applications. This segment also provides other silicate derivatives, including metasilicates, spray dried silicates, and magnesium and potassium silicates for use in cleaning, specialty fertilizer, oil and gas, mining, paint, food, and cosmetic applications, as well as zeolites for use as builders for detergents and other applications, such as stabilizers for the production of polyvinylchloride applications. PQ Group Holdings Inc. was founded in 1831 and is headquartered in Malvern, Pennsylvania.

Full PQG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PQG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PQG vs SCHDPQG vs JEPIPQG vs OPQG vs KOPQG vs MAINPQG vs JNJPQG vs MRKPQG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.